EP Patent

EP3597741A1 — Genetic correction of mutated genes

Assigned to Duke University · Expires 2020-01-22 · 6y expired

What this patent protects

Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.

USPTO Abstract

Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.

Drugs covered by this patent

Patent Metadata

Patent number
EP3597741A1
Jurisdiction
EP
Classification
—
Expires
2020-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Duke University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.